KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Pacira BioSciences (PCRX) over the last 13 years, with Q3 2025 value amounting to $4.1 million.

  • Pacira BioSciences' Tax Provisions fell 1123.64% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year decrease of 4307.21%. This contributed to the annual value of $36.5 million for FY2024, which is 8461.46% up from last year.
  • Pacira BioSciences' Tax Provisions amounted to $4.1 million in Q3 2025, which was down 1123.64% from $2.9 million recorded in Q2 2025.
  • Pacira BioSciences' 5-year Tax Provisions high stood at $17.7 million for Q2 2024, and its period low was -$8.0 million during Q4 2022.
  • For the 5-year period, Pacira BioSciences' Tax Provisions averaged around $4.2 million, with its median value being $4.1 million (2025).
  • As far as peak fluctuations go, Pacira BioSciences' Tax Provisions skyrocketed by 1573571.43% in 2021, and later crashed by 158884.12% in 2023.
  • Pacira BioSciences' Tax Provisions (Quarter) stood at -$1.1 million in 2021, then plummeted by 645.88% to -$8.0 million in 2022, then skyrocketed by 211.1% to $8.8 million in 2023, then increased by 7.18% to $9.5 million in 2024, then tumbled by 56.86% to $4.1 million in 2025.
  • Its Tax Provisions was $4.1 million in Q3 2025, compared to $2.9 million in Q2 2025 and $3.9 million in Q1 2025.